GleamWall
中文EN

DMRA Damora Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1800315 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,741.0%
TTM EPS YoY179.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-116.1%
ROA-107.4%
ROIC (approx.)-331.3%
Asset turnover—

Leverage & solvency

Liabilities / assets6.9%
Debt / equity0.00x
Current ratio14.80x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.20x
Accruals ratio-85.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$25.48M$25.54M$23.78M$23.32M$1.42M$1.47M$678,000$1.01M
SG&A expense$11.39M$9.45M$7.03M$4.07M$1.74M$1.96M$1.92M$1.70M
Operating income-$36.86M-$34.99M-$30.81M-$201.70M-$3.16M-$3.42M-$2.60M-$7.10M
Pretax income-$31.99M-$30.92M-$27.74M-$200.69M-$3.13M-$3.43M-$2.53M-$6.75M
Income tax$0$255,000$42,000$44,000$0$4,000$2,000-$8,000
Net income-$31.99M-$31.17M-$27.78M-$200.74M-$3.13M-$3.44M-$2.53M-$6.74M
EBITDA-$36.86M-$34.99M-$30.81M-$201.69M-$3.15M-$3.42M-$2.59M-$7.10M
EPS (basic)-0.40-0.39-0.62—-2.36-2.60-1.92—
EPS (diluted)-0.40-0.39-0.62—-2.36-2.60-1.92—
Dividends declared per share0.000.000.00—————
Weighted avg. shares (diluted)61.81M61.12M34.30M—1.33M1.32M1.32M—
Banking
Net interest income$4.16M$4.06M$3.07M$1.00M$42,000$50,000$74,000$228,000
Balance sheet
Cash & equivalents$349.66M$540.51M$532.90M$257.62M$7.61M$10.21M$11.94M$14.18M
Short-term investments$178.82M——$0————
Current assets$531.32M$543.59M$535.41M$260.42M$9.79M$13.03M$14.92M$16.84M
PP&E, net———$36,000$41,000$47,000$52,000$57,000
Total assets$532.63M$543.64M$535.44M$260.53M$10.74M$13.69M$15.37M$17.13M
Current liabilities$35.89M$27.55M$23.81M$20.07M$2.62M$2.63M$1.55M$1.20M
Total liabilities$36.87M$27.58M$23.84M$20.15M$2.73M$2.74M$1.66M$1.30M
Shareholders' equity$495.76M$516.06M$511.60M$239.04M$6.67M$9.61M$13.71M$14.47M
Shares outstanding61.90M61.73M60.30M1.60M1.33M1.32M1.32M1.32M
Cash flow statement
Operating cash flow-$17.23M-$21.87M-$20.60M$566,000-$2.62M-$2.24M-$2.44M-$4.94M
Investing cash flow———————$0
Financing cash flow$5.12M$29.50M$295.92M—————
Depreciation & amortization$5,000$6,000$5,000$6,000$6,000$6,000$5,000$5,000
Stock-based compensation$9.88M$10.69M$3.13M$483,000$164,000$172,000$179,000$308,000

Free plan shows the latest 8 periods; Pro shows all 29 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.